Charles River Laboratories Intl. Inc (NYSE:CRL) is Congress Asset Management Co. MA’s 9th Largest Position

Share on StockTwits

Congress Asset Management Co. MA lessened its stake in Charles River Laboratories Intl. Inc (NYSE:CRL) by 1.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 812,206 shares of the medical research company’s stock after selling 15,235 shares during the quarter. Charles River Laboratories Intl. makes up approximately 1.4% of Congress Asset Management Co. MA’s holdings, making the stock its 9th biggest holding. Congress Asset Management Co. MA owned about 1.69% of Charles River Laboratories Intl. worth $109,274,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the stock. NumerixS Investment Technologies Inc acquired a new position in Charles River Laboratories Intl. in the 2nd quarter valued at approximately $122,000. Wsfs Capital Management LLC acquired a new position in Charles River Laboratories Intl. in the 2nd quarter valued at approximately $203,000. CIBC Private Wealth Group LLC acquired a new position in Charles River Laboratories Intl. in the 2nd quarter valued at approximately $212,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Charles River Laboratories Intl. during the 2nd quarter worth $212,000. Finally, Visionary Asset Management Inc. acquired a new position in shares of Charles River Laboratories Intl. during the 2nd quarter worth $214,000. 97.31% of the stock is owned by institutional investors and hedge funds.

NYSE:CRL opened at $130.88 on Friday. The stock has a market cap of $6.29 billion, a PE ratio of 24.83, a price-to-earnings-growth ratio of 1.84 and a beta of 0.74. Charles River Laboratories Intl. Inc has a 52 week low of $96.70 and a 52 week high of $138.89. The company has a quick ratio of 1.32, a current ratio of 1.55 and a debt-to-equity ratio of 1.32.

Charles River Laboratories Intl. (NYSE:CRL) last released its quarterly earnings data on Wednesday, November 7th. The medical research company reported $1.53 EPS for the quarter, topping analysts’ consensus estimates of $1.38 by $0.15. Charles River Laboratories Intl. had a net margin of 6.39% and a return on equity of 25.08%. The company had revenue of $585.30 million during the quarter, compared to the consensus estimate of $567.58 million. During the same period last year, the firm earned $1.30 EPS. The firm’s revenue for the quarter was up 26.1% compared to the same quarter last year. On average, equities research analysts expect that Charles River Laboratories Intl. Inc will post 5.92 EPS for the current year.

Several brokerages have recently commented on CRL. Morgan Stanley increased their price target on shares of Charles River Laboratories Intl. from $102.00 to $112.00 and gave the stock a “hold” rating in a research note on Tuesday, September 11th. Barclays increased their price target on shares of Charles River Laboratories Intl. from $110.00 to $120.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 9th. ValuEngine lowered shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Wednesday, October 24th. Credit Suisse Group raised their target price on shares of Charles River Laboratories Intl. from $121.00 to $128.00 and gave the company a “neutral” rating in a research note on Tuesday, September 25th. Finally, Raymond James raised their target price on shares of Charles River Laboratories Intl. from $140.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday, November 8th. Eight equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $130.56.

In other Charles River Laboratories Intl. news, insider David P. Johst sold 23,356 shares of the firm’s stock in a transaction dated Wednesday, November 7th. The shares were sold at an average price of $136.00, for a total value of $3,176,416.00. Following the completion of the sale, the insider now owns 219,849 shares in the company, valued at approximately $29,899,464. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Deborah Turner Kochevar sold 4,066 shares of the firm’s stock in a transaction dated Tuesday, September 4th. The shares were sold at an average price of $123.66, for a total transaction of $502,801.56. Following the completion of the sale, the director now owns 10,190 shares of the company’s stock, valued at approximately $1,260,095.40. The disclosure for this sale can be found here. Insiders have sold a total of 29,288 shares of company stock valued at $3,930,176 over the last three months. 2.10% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY NOTICE: This report was published by BBNS and is the property of of BBNS. If you are accessing this report on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The original version of this report can be read at https://baseballnewssource.com/2018/11/18/charles-river-laboratories-intl-inc-crl-shares-sold-by-congress-asset-management-co-ma/2886563.html.

Charles River Laboratories Intl. Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Recommended Story: Bond

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.